KR880009948A - 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체 - Google Patents

항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체 Download PDF

Info

Publication number
KR880009948A
KR880009948A KR1019880001784A KR880001784A KR880009948A KR 880009948 A KR880009948 A KR 880009948A KR 1019880001784 A KR1019880001784 A KR 1019880001784A KR 880001784 A KR880001784 A KR 880001784A KR 880009948 A KR880009948 A KR 880009948A
Authority
KR
South Korea
Prior art keywords
compound
tetrazol
methylethoxy
methoxy
naphthalene carboxamide
Prior art date
Application number
KR1019880001784A
Other languages
English (en)
Inventor
토마스 코너 데이비드
찰스 어낭스트 폴
제임스 웨이커트 로보트
Original Assignee
크리스틴 에이. 트라우드웨인
워너-램버트 콤파니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 크리스틴 에이. 트라우드웨인, 워너-램버트 콤파니 filed Critical 크리스틴 에이. 트라우드웨인
Publication of KR880009948A publication Critical patent/KR880009948A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C07D257/06—Five-membered rings with nitrogen atoms directly attached to the ring carbon atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

내용 없음.

Description

항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (15)

  1. 식중, X는 산소 또는 황이고；R3는 C1내지 C12원자의 알킬이고 R1및 R2는 독립적으로 수소, 저급알킬, 저급알콕시, 머르캅토, 할로겐, 트리플루오로메틸, 저급 알킬티오, 저급 알킬설피닐, 저급 알킬설포닐, 하이드록시, 니트로, 아미노, 모노 저급 알킬 또는 디 저급 알킬아미노이고 S가 산화상태를 혼합하지 않는다는 조건으로 공히메틸렌 디옥시를 취함. 인 일반식(Ⅰ)의 화합물 및 이의 제약학적으로 허용가능한 염.
  2. 제1항에 있어서, R3가 이소프로필인 화합물.
  3. 제1항에 있어서, X가 산소인 화합물.
  4. 제1항에 있어서, R1및 R2가 5- 및 6- 또는 7- 및 8-위치에 있는 화합물.
  5. 제3항에 있어서, 화합물이 6-메톡시-1-(1-메틸 에톡시)-N-1H-테트라졸-5-일-2-나프탈렌카르복사이드인 화합물.
  6. 제5항의, 나트륨염.
  7. 제3항에 있어서, 화합물이 1-(1-메틸에톡시)-N-1H-테트라졸-5-일-2-나프탈렌 카르복사미드인 화합물.
  8. 제3항에 있어서, 화합물이 1,7-디메톡시-N-1H-테트라졸-5-일-2-나프탈렌 카르복사미드인 화합물.
  9. 제3항에 있어서, 화합물이 5-메톡시-1-(1-메틸에톡시)-N-1H-테트라졸-5-일-2-나프탈렌 카르복사미드인 화합물.
  10. 제3항에 있어서, 화합물이 7-메톡시-1-(1-메틸에톡시)-N-1H-테트라졸-5-일-2-나프탈렌 카르복사미드인 화합물.
  11. 제10항의 나트륨 염.
  12. 제3항에 있어서, 화합물이 1,7-bis(1-메틸에톡시)-N-1H-테트라졸-5-일-2-나프탈렌카르복사미드인 화합물.
  13. 호염기성 백혈구로부터 방출을 억제하여 제1항의 화합물의 유효량으로 구성하는 호염기성 백혈구로부터 히스타민 방출을 억제로부터 유리한 효과를 갖는 질병 또는 상태를 치료하기 위한 제약학적인 조성물 및 제약학적으로 허용 가능한 담체.
  14. 단위 복용 형태에서 제1항의 화합물로부터 유리한 효과를 갖는 포유동물에게 투약하는 호염기성 백혈구로부터 히스타민 방출을 억제하기 위해 포유류를 치료하는 방법.
  15. 일반식의 화합물.
    [식중, R1,R2및 R3는 상기한 바와 같음 이 일반식 I의 화합물을 얻기 위해 일반식화합물.
    로 처리된 제1항의 화합물을 제조하기 위한 방법.
    ※참고사항:최초출원 내용에 의하여 공개하는 것임.
KR1019880001784A 1987-02-20 1988-02-20 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체 KR880009948A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/016,811 US4767776A (en) 1987-02-20 1987-02-20 N-1H-tetrazol-5-yl-2-naphthalene carboxamides and their use as antiallergy and antiinflammatory agents
US016811 1987-02-20

Publications (1)

Publication Number Publication Date
KR880009948A true KR880009948A (ko) 1988-10-06

Family

ID=21779114

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880001784A KR880009948A (ko) 1987-02-20 1988-02-20 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체

Country Status (16)

Country Link
US (1) US4767776A (ko)
EP (1) EP0279466B1 (ko)
JP (1) JPS63222161A (ko)
KR (1) KR880009948A (ko)
AT (1) ATE89556T1 (ko)
AU (1) AU596054B2 (ko)
DE (1) DE3881073T2 (ko)
DK (1) DK84088A (ko)
ES (1) ES2054715T3 (ko)
FI (1) FI880748A (ko)
IE (1) IE61482B1 (ko)
NO (1) NO880731L (ko)
NZ (1) NZ223477A (ko)
PH (1) PH24687A (ko)
PT (1) PT86785B (ko)
ZA (1) ZA88385B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5257726A (en) * 1985-08-14 1993-11-02 Ing. Erich Pfeiffer Gmbh & Co. Kg Dispenser for flowable media
US5073566A (en) * 1989-11-30 1991-12-17 Eli Lilly And Company Angiotensin ii antagonist 1,3-imidazoles and use thereas
US5434188A (en) * 1994-03-07 1995-07-18 Warner-Lambert Company 1-ether and 1-thioether-naphthalene-2-carboxamides as inhibitors of cell adhesion and as inhibitors of the activation of HIV
DE60234057D1 (de) 2001-07-25 2009-11-26 Raptor Pharmaceutical Inc Zusammensetzungen und verfahren zur modulation des transports durch die blut-hirn-schranke
AU2003229142A1 (en) * 2002-06-07 2003-12-22 Cortical Pty Ltd Naphthalene derivatives which inhibit the cytokine or biological activity of macrophage inhibitory factor (MIF)
JP2006526606A (ja) * 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー 治療薬としてのシクロアルキル及びヘテロシクロアルキル置換されるベンゾチオフェン
JP2006526608A (ja) * 2003-06-05 2006-11-24 ワーナー−ランバート カンパニー リミティド ライアビリティー カンパニー Ｐｉ３ｋ活性を有する治療薬としてのテトラゾールベンゾフランカルボキシアミド
MXPA05012953A (es) * 2003-06-05 2006-02-13 Warner Lambert Co Benzo[b]tiofenos 3-arilsulfanil y 3-heteroarilsulfanil sustituidos como agentes terapeuticos.
ATE365735T1 (de) * 2003-06-05 2007-07-15 Warner Lambert Co Cycloalkylsulfanyl-substituierte benzo böthiophene als therapeutische mittel
US20040259926A1 (en) * 2003-06-05 2004-12-23 Bruendl Michelle M. 3-Aryloxy and 3-heteroaryloxy substituted benzo[b]thiophenes as therapeutic agents
CA2527779A1 (en) * 2003-06-05 2004-12-16 Warner-Lambert Company Llc 3-substituted indoles and derivatives thereof as therapeutic agents
US7318709B2 (en) * 2003-08-27 2008-01-15 Haldex Brake Corporation Pump valve assembly
EP2392258B1 (en) 2005-04-28 2014-10-08 Proteus Digital Health, Inc. Pharma-informatics system
US8795627B2 (en) 2007-03-21 2014-08-05 Raptor Pharmaceuticals Inc. Treatment of liver disorders by administration of RAP conjugates
AU2010216512B2 (en) 2009-02-20 2016-06-30 2-Bbb Medicines B.V. Glutathione-based drug delivery system
WO2010129819A2 (en) 2009-05-06 2010-11-11 Laboratory Skin Care, Inc. Dermal delivery compositions comprising active agent-calcium phosphate particle complexes and methods of using the same
US20120077778A1 (en) 2010-09-29 2012-03-29 Andrea Bourdelais Ladder-Frame Polyether Conjugates
ES2659553T3 (es) 2011-12-21 2018-03-16 Syngenta Limited Compuestos herbicidas
EP2855446A2 (en) * 2012-04-27 2015-04-08 Basf Se Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides
WO2014184073A1 (en) * 2013-05-15 2014-11-20 Basf Se Substituted n-(tetrazol-5-yl)- and n-(triazol-5-yl)arylcarboxamide compounds and their use as herbicides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1343827A (en) * 1971-06-15 1974-01-16 Science Union & Cie Acylaminotetrazoles and process for preparing them
BE789822A (fr) * 1971-10-08 1973-04-06 Allen & Hanburys Ltd Nouveaux composes heterocycliques
US4145350A (en) * 1972-09-06 1979-03-20 Burroughs Wellcome Co. Cyclic sulphur compounds triazolyl substituted phenoxathin 10, 10 dioxides
GB1561350A (en) * 1976-11-05 1980-02-20 May & Baker Ltd Benzamide derivatives
US4147694A (en) * 1977-02-07 1979-04-03 Riker Laboratories, Inc. 8-(1H-Tetrazol-5-yl-carbamoyl)quinoline compounds
US4474792A (en) * 1979-06-18 1984-10-02 Riker Laboratories, Inc. N-Tetrazolyl benzamides and anti-allergic use thereof
US4432986A (en) * 1979-06-18 1984-02-21 Riker Laboratories, Inc. Tetrazoles bonded to certain polycyclic aromatic systems and anti-allergic use thereof

Also Published As

Publication number Publication date
PT86785B (pt) 1992-05-29
DE3881073T2 (de) 1993-09-02
NO880731D0 (no) 1988-02-19
EP0279466A3 (en) 1989-08-02
NO880731L (no) 1988-08-22
DK84088D0 (da) 1988-02-18
AU596054B2 (en) 1990-04-12
NZ223477A (en) 1990-01-29
DE3881073D1 (de) 1993-06-24
IE61482B1 (en) 1994-11-02
IE880125L (en) 1988-08-20
DK84088A (da) 1988-08-21
FI880748A0 (fi) 1988-02-17
FI880748A (fi) 1988-08-21
EP0279466A2 (en) 1988-08-24
PT86785A (pt) 1988-03-01
EP0279466B1 (en) 1993-05-19
US4767776A (en) 1988-08-30
AU1111988A (en) 1988-09-01
JPS63222161A (ja) 1988-09-16
ES2054715T3 (es) 1994-08-16
ATE89556T1 (de) 1993-06-15
PH24687A (en) 1990-09-07
ZA88385B (en) 1989-09-27

Similar Documents

Publication Publication Date Title
KR880009948A (ko) 항 알레르기 및 항 염증제로서 용도를 갖는 신규의 나프탈렌 유도체
DE60024407D1 (de) (2-imidazolin-2-ylamino)quinoxaline zur behandlung von neuralen verletzungen
NO981528L (no) Substituerte imidazoler med antikreft- og cytokininhibitoraktivitet
ATE60761T1 (de) Chinazolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
ES2142861T3 (es) Derivados de 4-(1h-2-metilimidazo(4,5-c)piridinilmetil)fenilsulfonamida como antagonistas del paf.
ATE448194T1 (de) Verwendung einer pharmazeutischen zusammensetzung mit einem para-aminophenylessigsäurederivat für die behandlung von entzündlichen erkrankungen des magen-darmtrakts
KR880006193A (ko) 피페리딘 화합물 및 그의 제조 및 용도
ES8707947A1 (es) Un procedimiento para la preparacion de acidos 3-hidroxifenoxialquilenheterociclilcarboxilicos.
AR029190A1 (es) Composiciones que contienen derivados del acido hidroxieicosatetraenoico y uso para la manufactura de un medicamento en el tratamiento de trastornos del ojo seco
MD1688F2 (en) Benzothiophene, benzofuran and indolethiazepinons, oxazepinons and diazepinons, pharmaceutical composition, method of inhibiting the leucocytes adherence to the endothelial cells for inflammatory diseases treatment and method of treatment of the mammals affected by the HIV infection
ES2100222T3 (es) Derivados del acido aminoalcansulfonico y compuestos farmaceuticos a utilizar para prevenir o tratar afecciones cardiacas.
KR960007565A (ko) 약제로서의 치환된 4-페닐-6-아미노-니코틴산 유도체의 용도
KR890011596A (ko) 불면증 치료용 의약품의 제조에 있어서 1,4-이치환-피페리디닐 화합물의 용도
KR900016135A (ko) 피부 및 점막-상피의 질환 치료용 4-퀴놀린 카복실산 유도체
ATE156119T1 (de) 2-formylpyridin-thiosemicarbazonderivate, ihre herstellung und ihre verwendung als antitumor mittel
RU94045271A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования синдрома тернера
ATE26273T1 (de) 3-indolcarboxamid-verbindungen.
IT1196423B (it) Benzotiazolin-composti
KR880007462A (ko) 빈뇨치료용 프로피오페논 유도체
ATE169217T1 (de) Verwendung von furanonderivaten zur vorbeugung oder behandlung von autoimmunkrankheiten
ITMI922742A1 (it) Composti ad attivita' terapeutica utili per il trattamento di malattie connesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
KR880001596A (ko) 디하이드로피리딘 화합물-함유 뇌기능이상 치료제
EP0228314A3 (en) Use of ethanol/amine derivatives in treating or preventing hyperlipemia
NZ216110A (en) 4-(z)-6-((2,4,5-cis -2-alkyl-4-(2-hydroxyphenyl)-1,3- dioxan-5-yl) hexenoic acid derivatives and pharmaceutical compositions
ES531318A0 (es) Procedimiento para la obtencion de derivados quinolinicos

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid